SCHEMBL30649645

CC(=O)N[C@H]1[C@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](O)O[C@@H]3CO)O[C@H](CO)[C@@H]2O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2NC(C)=O)O[C@H](CO)[C@@H](O[C@@H]2O[C@H](CO)[C@H](O[C@@H]3O[C@H](CO)[C@H](O)[C@H](O)[C@H]3NC(C)=O)[C@H](O[C@]3(C(=O)O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O3)[C@H]2O)[C@@H]1O

nearest known ligand 0.64

Predicted protein targets (top 5)

	gene	UniProt	supporting neighbours	confidence
▸	SIGLEC7	Q9Y286	6/20	0.64

▸	SELP	P16109	2/20	0.63

▸	SELL	P14151	1/20	0.63

▸	MAG	P20916	8/20	0.62

▸	SELE	P16581	3/20	0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL29532719	0.99	SELP (0.64)	SIGLEC7SELPSELLMAGSELE
SCHEMBL29868336	0.99	SELP (0.64)	SIGLEC7SELPSELLMAGSELE
SCHEMBL30649566	0.98	SIGLEC7 (0.67)	SIGLEC7SELPSELLMAGSELE
SCHEMBL30652425	0.98	SIGLEC7 (0.65)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31700330	0.98	MAG (0.66)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31701547	0.97	MAG (0.66)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31700826	0.96	SELP (0.64)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31701590	0.96	MAG (0.66)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31700436	0.96	MAG (0.66)	SIGLEC7SELPSELLMAGSELE
SCHEMBL31700526	0.96	MAG (0.66)	SIGLEC7SELPSELLMAGSELE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20250319190-A1	APOE LIPOPROTEIN SYSTEMS	KISBEE THERAPEUTICS INC (US)	2025-10-16	—	—	US	disclosed
EP-4522646-A2	APOE LIPOPROTEIN SYSTEMS	Kisbee Therapeutics, Inc. (US)	2025-03-19	—	—	EP	disclosed
WO-2023220387-A2	APOE LIPOPROTEIN SYSTEMS	KISBEE THERAPEUTICS, INC. (US)	2023-11-16	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20250319190-A1	APOE LIPOPROTEIN SYSTEMS	APOB, APOL1, LDLR	SIGLEC7 692/4885SELP 158/4885SELL 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.